CCO Oncology Podcast

CDK4/6 Inhibitors in HR-Positive/HER2-Negative Breast Cancer: Experts Answer Your Questions

Episode Summary

Listen to Drs William J. Gradishar, Heather McArthur, and Joanne Mortimer address key questions on the use of CDK4/6 inhibitors in HR-positive/HER2-negative breast cancer treatment. The discussion covers genomic testing options, adjuvant treatment duration, toxicity management topics, and how the available clinical data and updated guidelines influence therapeutic decisions.

Episode Notes

In this episode, Drs William J. Gradishar, Heather McArthur, and Joanne Mortimer address audience questions from a recent live event on the use of CDK4/6 inhibitors in patients with early and metastatic breast cancer, including:

• Genomic testing options for assessing risk of recurrence
• Adjuvant treatment duration and holidays with CDK4/6 inhibitors
• Managing renal toxicities, prophylaxis for DVT, and asymptomatic ILD
• CDK4/6 inhibitors with inavolisib and fulvestrant

Presenters:
William J. Gradishar, MD, FACP, FASCO
Betsy Bramsen Professor of Breast Oncology
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, Illinois

Heather McArthur, MD, MPH, FASCO
Professor, Department of Internal Medicine
Clinical Director, Breast Cancer Program
Komen Distinguished Chair in Clinical Breast Cancer Research
UT Southwestern Medical Center
Dallas, Texas

Joanne Mortimer, MD, FACP, FASCO
Vice Chair, Medical Oncology
Professor, Division of Medical Oncology & Experimental Therapeutics
Associate Director for Education and Training
Baum Family Professor of Women’s Cancers
City of Hope Comprehensive Cancer Center
Duarte, California

Link to full program:
https://bit.ly/4osHLTm